Induction of granzyme B expression in T-cell receptor/CD28-stimulated human regulatory T cells is suppressed by inhibitors of the PI3K-mTOR pathway

BMC Immunology

Volumn 10, Issue , 2009, Pages

  Efimova, Olga V ^a   Kelley, Todd W ^a,b  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CD28 ANTIGEN; CD3 ANTIGEN; GRANZYME B; INTERLEUKIN 2; PHOSPHATIDYLINOSITOL 3 KINASE; RAPAMYCIN; T LYMPHOCYTE RECEPTOR; 2-(4-MORPHOLINYL)-8-PHENYL-4H-1-BENZOPYRAN-4-ONE; CHROMONE DERIVATIVE; GRANZYME; LYMPHOCYTE ANTIGEN RECEPTOR; MAMMALIAN TARGET OF RAPAMYCIN; MORPHOLINE DERIVATIVE; PROTEIN SERINE THREONINE KINASE; SIGNAL PEPTIDE;

ARTICLE; CD4+ T LYMPHOCYTE; CELL EXPANSION; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INDUCTION; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; LYMPHOCYTE PROLIFERATION; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; BIOSYNTHESIS; CELL CULTURE; CELL PROLIFERATION; CYTOLOGY; DRUG ANTAGONISM; DRUG EFFECT; GENETICS; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE SUBPOPULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANTIGENS, CD28; CELL PROLIFERATION; CELLS, CULTURED; CHROMONES; CYTOTOXICITY, IMMUNOLOGIC; GRANZYMES; HUMANS; INTERLEUKIN-2; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MORPHOLINES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, ANTIGEN, T-CELL; SIGNAL TRANSDUCTION; SIROLIMUS; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, REGULATORY;

EID: 71549135853     PISSN: None     EISSN: 14712172     Source Type: Journal    
DOI: 10.1186/1471-2172-10-59     Document Type: Article

References (40)

1. Miyara M, Sakaguchi S. Natural regulatory T cells: mechanisms of suppression. Trends Mol Med 2007, 13:108-16. 10.1016/j.molmed.2007.01.003, 17257897.
2. Zhao DM, Thornton AM, DiPaolo RJ, Shevach EM. Activated CD4+CD25+ T cells selectively kill B lymphocytes. Blood 2006, 107:3925-32. 10.1182/blood-2005-11-4502, 1895290, 16418326.
3. Gondek DC, Lu LF, Quezada SA, Sakaguchi S, Noelle RJ. Cutting edge: contact-mediated suppression by CD4+CD25+ regulatory cells involves a granzyme B-dependent, perforin-independent mechanism. J Immunol 2005, 174:1783-6.
4. Cao X, Cai SF, Fehniger TA, Song J, Collins LI, Piwnica-Worms DR, Ley TJ. Granzyme B and perforin are important for regulatory T cell-mediated suppression of tumor clearance. Immunity 2007, 27:635-46. 10.1016/j.immuni.2007.08.014, 17919943.
5. Gondek DC, Devries V, Nowak EC, Lu LF, Bennett KA, Scott ZA, Noelle RJ. Transplantation survival is maintained by granzyme B+ regulatory cells and adaptive regulatory T cells. J Immunol 2008, 181:4752-60. 2572718, 18802078.
6. Chai JG, Coe D, Chen D, Simpson E, Dyson J, Scott D. In vitro expansion improves in vivo regulation by CD4+CD25+ regulatory T cells. J Immunol 2008, 180:858-69.
7. Sadlack B, Merz H, Schorle H, Schimpl A, Feller AC, Horak I. Ulcerative colitis-like disease in mice with a disrupted interleukin-2 gene. Cell 1993, 75:253-61. 10.1016/0092-8674(93)80067-O, 8402910.
8. Suzuki H, Kundig TM, Furlonger C, Wakeham A, Timms E, Matsuyama T, Schmits R, Simard JJ, Ohashi PS, Griesser H. Deregulated T cell activation and autoimmunity in mice lacking interleukin-2 receptor beta. Science 1995, 268:1472-6. 10.1126/science.7770771, 7770771.
9. Sadlack B, Lohler J, Schorle H, Klebb G, Haber H, Sickel E, Noelle RJ, Horak I. Generalized autoimmune disease in interleukin-2-deficient mice is triggered by an uncontrolled activation and proliferation of CD4+ T cells. Eur J Immunol 1995, 25:3053-9. 10.1002/eji.1830251111, 7489743.
10. Soper DM, Kasprowicz DJ, Ziegler SF. IL-2Rbeta links IL-2R signaling with Foxp3 expression. Eur J Immunol 2007, 37:1817-26. 10.1002/eji.200737101, 17559173.
11. Burchill MA, Yang J, Vogtenhuber C, Blazar BR, Farrar MA. IL-2 receptor beta-dependent STAT5 activation is required for the development of Foxp3+ regulatory T cells. J Immunol 2007, 178:280-90.
12. Tamang DL, Redelman D, Alves BN, Vollger L, Bethley C, Hudig D. Induction of granzyme B and T cell cytotoxic capacity by IL-2 or IL-15 without antigens: multiclonal responses that are extremely lytic if triggered and short-lived after cytokine withdrawal. Cytokine 2006, 36:148-59. 10.1016/j.cyto.2006.11.008, 1850105, 17188506.
13. Zhou J, Meadows GG. Alcohol consumption decreases IL-2-induced NF-kappaB activity in enriched NK cells from C57BL/6 mice. Toxicol Sci 2003, 73:72-9. 10.1093/toxsci/kfg047, 12700414.
14. Huang C, Bi E, Hu Y, Deng W, Tian Z, Dong C, Hu Y, Sun B. A novel NF-kappaB binding site controls human granzyme B gene transcription. J Immunol 2006, 176:4173-81.
15. Crellin NK, Garcia RV, Levings MK. Altered activation of AKT is required for the suppressive function of human CD4+CD25+ T regulatory cells. Blood 2007, 109:2014-22. 10.1182/blood-2006-07-035279, 17062729.
16. Haxhinasto S, Mathis D, Benoist C. The AKT-mTOR axis regulates de novo differentiation of CD4+Foxp3+ cells. J Exp Med 2008, 205:565-74. 10.1084/jem.20071477, 2275380, 18283119.
17. Bensinger SJ, Walsh PT, Zhang J, Carroll M, Parsons R, Rathmell JC, Thompson CB, Burchill MA, Farrar MA, Turka LA. Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells. J Immunol 2004, 172:5287-96.
18. Korczak-Kowalska G, Wierzbicki P, Bocian K, Klosowska D, Niemczyk M, Wyzgal J, Korecka A, Durlik M, Chmura A, Paczek L. The influence of immuosuppressive therapy on the development of CD4+CD25+ T cells after renal transplantation. Transplant Proc 2007, 39:2721-3. 10.1016/j.transproceed.2007.09.015, 18021968.
19. Segundo DS, Ruiz JC, Izquierdo M, Fernandez-Fresnedo G, Gomez-Alamillo C, Merino R, Benito MJ, Cacho E, Rodrigo E, Palomar R. Calcineurin inhibitors, but not rapamycin, reduce percentages of CD4+CD25+FOXP3+ regulatory T cells in renal transplant recipients. Transplantation 2006, 82:550-7. 10.1097/01.tp.0000229473.95202.50, 16926600.
20. Zeiser R, Leveson-Gower DB, Zambricki EA, Kambham N, Beilhack A, Loh J, Hou JZ, Negrin RS. Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells. Blood 2008, 111:453-62. 10.1182/blood-2007-06-094482, 2200823, 17967941.
21. Battaglia M, Stabilini A, Roncarolo MG. Rapamycin selectively expands CD4+CD25+FoxP3+ regulatory T cells. Blood 2005, 105:4743-8. 10.1182/blood-2004-10-3932, 15746082.
22. Nikolaeva N, Bemelman FJ, Yong SL, van Lier RA, ten Berge IJ. Rapamycin does not induce anergy but inhibits expansion and differentiation of alloreactive human T cells. Transplantation 2006, 81:445-54. 10.1097/01.tp.0000194860.21533.b9, 16477233.
23. Kuypers DR, Herelixka A, Vanrenterghem Y. Clinical use of rapamycin in renal allograft recipients identifies its relevant toxicity profile and raises unsolved questions: a single-center experience. Transplant Proc 2003, 35:138S-142S. 10.1016/S0041-1345(03)00246-X, 12742486.
24. Liu W, Putnam AL, Xu-Yu Z, Szot GL, Lee MR, Zhu S, Gottlieb PA, Kapranov P, Gingeras TR, Fazekas de St Groth B. CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells. J Exp Med 2006, 203:1701-11. 10.1084/jem.20060772, 2118339, 16818678.
25. Golovina TN, Mikheeva T, Suhoski MM, Aqui NA, Tai VC, Shan X, Liu R, Balcarcel RR, Fisher N, Levine BL. CD28 costimulation is essential for human T regulatory expansion and function. J Immunol 2008, 181:2855-68. 2556987, 18684977.
26. Horwitz DA, Gray JD, Zheng SG. The potential of human regulatory T cells generated ex vivo as a treatment for lupus and other chronic inflammatory diseases. Arthritis Res 2002, 4:241-6. 10.1186/ar414, 128930, 12106494.
27. Xia G, He J, Zhang Z, Leventhal JR. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Transplantation 2006, 82:1749-55. 10.1097/01.tp.0000250731.44913.ee, 17198271.
28. June CH. Adoptive T cell therapy for cancer in the clinic. J Clin Invest 2007, 117:1466-76. 10.1172/JCI32446, 1878537, 17549249.
29. Zheng SG, Meng L, Wang JH, Watanabe M, Barr ML, Cramer DV, Gray JD, Horwitz DA. Transfer of regulatory T cells generated ex vivo modifies graft rejection through induction of tolerogenic CD4+CD25+ cells in the recipient. Int Immunol 2006, 18:279-89. 10.1093/intimm/dxh368, 16415106.
30. Xia G, He J, Leventhal JR. Ex vivo-expanded natural CD4+CD25+ regulatory T cells synergize with host T-cell depletion to promote long-term survival of allografts. Am J Transplant 2008, 8:298-306.
31. Pu LY, Wang XH, Zhang F, Li XC, Yao AH, Yu Y, Lv L, Li GQ. Adoptive transfusion of ex vivo donor alloantigen-stimulated CD4(+)CD25(+) regulatory T cells ameliorates rejection of DA-to-Lewis rat liver transplantation. Surgery 2007, 142:67-73. 10.1016/j.surg.2007.02.014, 17630002.
32. Chen W, Jin W, Hardegen N, Lei KJ, Li L, Marinos N, McGrady G, Wahl SM. Conversion of peripheral CD4+CD25- naive T cells to CD4+CD25+ regulatory T cells by TGF-beta induction of transcription factor Foxp3. J Exp Med 2003, 198:1875-86. 10.1084/jem.20030152, 2194145, 14676299.
33. Pyzik M, Piccirillo CA. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. J Leukoc Biol 2007, 82:335-46. 10.1189/jlb.1006644, 17475784.
34. Zheng SG, Wang J, Wang P, Gray JD, Horwitz DA. IL-2 is essential for TGF-beta to convert naive CD4+CD25- cells to CD25+Foxp3+ regulatory T cells and for expansion of these cells. J Immunol 2007, 178:2018-27.
35. Hoffmann P, Eder R, Kunz-Schughart LA, Andreesen R, Edinger M. Large-scale in vitro expansion of polyclonal human CD4(+)CD25 high regulatory T cells. Blood 2004, 104:895-903. 10.1182/blood-2004-01-0086, 15090447.
36. Takahashi T, Kuniyasu Y, Toda M, Sakaguchi N, Itoh M, Iwata M, Shimizu J, Sakaguchi S. Immunologic self-tolerance maintained by CD25+CD4+ naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int Immunol 1998, 10:1969-80. 10.1093/intimm/10.12.1969, 9885918.
37. Walsh PT, Buckler JL, Zhang J, Gelman AE, Dalton NM, Taylor DK, Bensinger SJ, Hancock WW, Turka LA. PTEN inhibits IL-2 receptor-mediated expansion of CD4+ CD25+ Tregs. J Clin Invest 2006, 116:2521-31. 1550279, 16917540.
38. Strauss L, Czystowska M, Szajnik M, Mandapathil M, Whiteside TL. Differential responses of human regulatory T cells (Treg) and effector T cells to rapamycin. PLoS One 2009, 4:e5994. 10.1371/journal.pone.0005994, 2694984, 19543393.
39. Grossman WJ, Verbsky JW, Barchet W, Colonna M, Atkinson JP, Ley TJ. Human T regulatory cells can use the perforin pathway to cause autologous target cell death. Immunity 2004, 21:589-601. 10.1016/j.immuni.2004.09.002, 15485635.
40. Grossman WJ, Verbsky JW, Tollefsen BL, Kemper C, Atkinson JP, Ley TJ. Differential expression of granzymes A and B in human cytotoxic lymphocyte subsets and T regulatory cells. Blood 2004, 104:2840-8. 10.1182/blood-2004-03-0859, 15238416.